3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Nautilus Biotechnology reported third quarter 2026 results for the period ended September 30, 2026, with revenue of $0.2 million, mainly grant revenue, compared with no revenue a year earlier. Net loss widened to $15.6 million from $13.6 million as operating expenses rose 10% to $16.9 million, and cash, cash equivalents and investments stood at $114.3 million at quarter end.
Q3 2026 revenue was $0.2 million, primarily grant revenue tied to a Michael J. Fox Foundation grant, versus no revenue in Q3 2025.
Operating expenses rose $1.5 million, or 10%, to $16.9 million, driven by higher laboratory, professional services and salary costs.
Net loss was $15.6 million, or $0.12 per share, compared with $13.6 million, or $0.11 per share, a year earlier.
Cash, cash equivalents and investments were $114.3 million as of September 30, 2026; the company said it expects up to $6 million from the ARPA-H-funded SEEDS consortium.
On October 20, 2026, Bold Eagle Acquisition Corp. shareholders approved extending the date to complete an initial business combination from October 25, 2026 to June 25, 2027. Holders of 15,397,025 Class A shares redeemed for about $10.70 per share, leaving about $111,311,833 in the trust account, but non-redemption agreements with several investors are expected to keep more funds in the trust than would otherwise remain.
Extension Amendment Proposal approved: 20,448,699 for, 497,774 against, 0 abstentions.
15,397,025 Class A shares redeemed at about $10.70 per share; about $111,311,833 left in the trust account.
Investors reversed their redemptions in exchange for monthly cash deposits of $134,507 into escrow, funded by the sponsor, until the earliest of a business combination closing, liquidation, or June 25, 2027.
Sponsor converted 5,159,999 Class B shares to Class A shares on October 23, 2026; 15,562,974 Class A shares were outstanding as of October 26, 2026.
FF EAI Robotics Ecosystem said it completed its acquisition of the robotics business of Faraday Future Intelligent Electric on October 23, 2026, paying with common and non-voting convertible preferred shares issued to a Faraday Future subsidiary. It also gave first-time full-year 2026 guidance of about 2,000 robots on a standalone basis, but the filing reports no revenue, profit, or EPS results, and the share issuance may dilute existing holders.
Acquisition closed October 23, 2026; consideration was common and non-voting convertible preferred shares issued to Smart Technology Holdings Ltd., a Faraday Future subsidiary
Standalone 2026 guidance of about 2,000 robots with positive unit gross margins; the company will consolidate the acquired business only from October 23, 2026
October sales and shipments expected to exceed 300 robots; cumulative sales expected to exceed 1,100 robots by month-end
Projected 2027 revenue of about $45.2 million under a five-year outlook that is not a guarantee of future performance
On October 20, 2026, iQSTEL issued senior secured, non-convertible promissory notes of up to $3 million in aggregate to M2B Funding Corp. and ADI Funding LLC, along with pre-funded warrants for 420,000 shares, to help fund its planned 51% acquisition of Ultranet Telecom Group. The notes carry 18% annual interest and are secured by a first-priority interest in company collateral, and the warrants could add dilution, so the financing adds debt cost and potential share issuance for shareholders while the acquisition itself is not yet signed.
Up to $3 million in notes, split between two purchasers: first $750,000 per purchaser funded on or about October 20, 2026, and a second advance of up to $750,000 per purchaser due on or before December 1, 2026
Notes bear 18% annual interest payable monthly in cash; principal repaid in four equal installments over 24 months
Warrants for 420,000 shares at a $0.0001 exercise price were fully issued at the initial closing; holders may accelerate at 120% of funded principal after an uncured default
Company expects to sign the Ultranet share purchase agreement in November 2026 and target closing in the middle of the first quarter of 2027
Venu Holding Corp and subsidiaries executed agreements on October 20, 2026, selling the approximately 46-acre McKinney Parcel under The Sunset McKinney to STORE Capital Acquisitions, LLC and amending its Chapter 380 agreement with the City of McKinney. The city agreement lets the company keep operating control but adds a $3,000,000 cap on certain annual operations incentives and reduces a separated materials tax grant, while the company expects to be reimbursed the full $35,000,000 land purchase price if it meets construction milestones.
Land sale to STORE and the McKinney Sale-Leaseback closed on October 20, 2026, the Execution Date.
The company expects reimbursement of the full $35,000,000 land price ($10,000,000 cash plus $25,000,000 MEDC Note) if a TCO is received by December 3, 2027, or a CO by June 3, 2028.
Certain annual operations incentives for years 12 through 16 are capped at $3,000,000 in aggregate.
The filing excerpt does not state the sale-leaseback sale price.
Brown & Brown reported unaudited third-quarter 2026 results on October 26, 2026, with total revenues of $1.7 billion, up 7.4%, and net income attributable to the Company of $240 million, up 5.7%. Diluted net income per share fell 1.5% to $0.67, while adjusted diluted net income per share rose 1.9% to $1.07, and margins declined from the prior-year quarter.
Total revenues of $1.7 billion, up 7.4%; Organic Revenue growth of 1.2%
Net income attributable to the Company of $240 million, up 5.7%
Diluted net income per share of $0.67, down 1.5%; adjusted diluted net income per share of $1.07, up 1.9%
Income Before Income Taxes Margin of 18.6% vs. 19.4%; EBITDAC Margin - Adjusted of 34.6% vs. 36.6%
Blue Ridge Bankshares reported a third-quarter 2026 net loss of $4.2 million, or ($0.05) per diluted share, wider than the $1.3 million loss in the second quarter and down from $5.6 million of net income a year earlier. Most of the credit provision tied to a single out-of-market loan relationship, while adjusted pre-tax earnings improved and the HomeTrust merger remains pending.
Net loss of $4.2 million, or ($0.05) per diluted share, versus net income of $5.6 million, or $0.06 per diluted share, in the third quarter of 2025.
Pre-tax provision for credit losses was $8.5 million, mainly linked to one out-of-market relationship; the company charged off $9.9 million on that borrower.
Adjusted pre-tax earnings rose to $5.3 million from $2.9 million in the second quarter of 2026.
HomeTrust merger agreement was announced August 17, 2026, and is expected to close in the first quarter of 2027, pending approvals.
Longeveron reported updated ELPIS II Phase 2b results for laromestrocel in 40 infants with hypoplastic left heart syndrome. The trial did not meet its primary endpoint of change in right ventricular ejection fraction at Month 12, but a pre-specified secondary endpoint, major adverse cardiac events (MACE), reached statistical significance. The company plans to request an FDA meeting, and the results are scheduled for presentation at the AHA 2026 Scientific Sessions.
Primary endpoint not met: mean RVEF decreased 2.6 percentage points in the standard of care group and 3.3 points in the laromestrocel group, with no statistically significant difference (p=0.68).
MACE: 8 events in the standard of care arm versus 1 in the laromestrocel arm (P=0.043).
FDA previously advised Longeveron that RVEF alone would not be sufficient to demonstrate efficacy for regulatory approval.
Data selected for a late-breaking podium presentation at AHA 2026 Scientific Sessions on November 8, 2026, in Chicago.
Flexsteel reported fiscal first-quarter 2027 results for the period ended September 30, 2026, with net sales up 3.2% to $114.0 million. Operating income fell to $6.9 million from $9.0 million, and diluted earnings per share dropped to $1.24 from $1.31, as gross margin declined on currency effects and higher energy and material costs. The company expects second-quarter sales of $119.5 million to $123.0 million and a GAAP operating margin of 6.5% to 7.0%.
Net sales were $114.0 million, up 3.2% from $110.4 million; Flexsteel-branded sales rose 5.1% while the exited Homestyles line fell 57.6%.
GAAP operating income was $6.9 million, or 6.0% of net sales, versus $9.0 million, or 8.1%, a year earlier.
Diluted EPS was $1.24 versus $1.31; net income was $5.4 million versus $7.3 million.
For the quarter ending December 2026, the company guides to sales of $119.5 million to $123.0 million (1% to 4% growth) and a 6.5% to 7.0% operating margin; a conference call is set for October 27, 2026 at 8:00 a.m. Central Time.
Cumberland Pharmaceuticals plans to submit a New Drug Application to the FDA for ifetroban as a treatment for cardiomyopathy associated with Duchenne muscular dystrophy, seeking Traditional Approval based on its FIGHT DMD trial and natural history data. The FDA raised concerns that the proposed data package may not be sufficient to show substantial evidence of efficacy and requested additional analysis, and the company states there is no assurance the FDA will accept the filing or approve the drug.
The 12-month Phase 2 FIGHT DMD trial showed a statistically significant 5.4% absolute improvement in left ventricular ejection fraction (p=0.002) versus a control group.
The FDA suggested a Phase 3, randomized, placebo-controlled trial earlier in the review process, and expressed concerns about the sufficiency of the proposed data package at a pre-NDA meeting held this fall.
The FDA granted the company's request for rolling review of the NDA, allowing completed sections to be submitted before the full application.
The planned submission includes safety data from more than 1,400 subjects across approximately 30 clinical studies of ifetroban.
Dorman Products reported third-quarter 2026 net sales of $561.7 million, up 3.3%, but diluted EPS fell 20% to $1.98 and adjusted diluted EPS fell 21% to $2.08. The company narrowed its full-year 2026 guidance, lowering the top end of its net sales growth range to 2% to 3% from 3% to 5%, which matters to shareholders because sales growth is slowing while profit is down from the prior year.
Net sales of $561.7 million, up 3.3% from $543.7 million; gross margin fell to 39.4% from 44.4%.
Diluted EPS of $1.98 vs. $2.48 a year earlier; adjusted diluted EPS of $2.08 vs. $2.62.
Full-year 2026 net sales growth guidance narrowed to 2% to 3% from 3% to 5%; adjusted diluted EPS guidance is $8.50 to $8.70, down from $8.50 to $8.80.
Repurchased $15 million of shares in the quarter; year-to-date repurchases total $112 million, a company record.
OpenWorld preliminarily estimated third-quarter 2026 revenue of $6.9 million to $7.2 million and a GAAP net loss of about $10.0 million, which includes about $11.9 million of nonrecurring stock-based compensation and merger-related fees. The company also named Gerard Hernandez Chief Financial Officer effective October 23, 2026, after removing Jennifer Cola from the role. The estimates are unaudited and not yet reviewed by the auditor, and the company will report final results on November 12, 2026.
Estimated Q3 2026 revenue of $6.9 million to $7.2 million, with gross margin of 80% to 82%
Estimated GAAP net loss of about $10.0 million, including about $11.9 million of nonrecurring stock-based compensation and merger-related fees
Estimated adjusted EBITDA (non-GAAP) of $1.7 million to $2.0 million
Gerard Hernandez named CFO effective October 23, 2026; Jennifer Cola was removed as CFO effective the same date
H2O America reported third quarter 2026 GAAP diluted EPS of $0.99, down from $1.27 a year earlier, while operating revenue rose 4% to $250.2 million on rate increases. The company narrowed its standalone 2026 adjusted EPS guidance to $3.10-$3.16 and set a separate 2026 guidance range of $2.91-$2.97 that includes the Quadvest and pending Cibolo Valley acquisitions, so shareholders face higher share count and acquisition-related dilution in the near term.
Q3 2026 GAAP net income was $43.0 million, down 5%; adjusted diluted EPS was $1.04 versus $1.27 a year earlier
Standalone 2026 adjusted EPS guidance narrowed to $3.10-$3.16, midpoint unchanged at $3.13; guidance including acquisitions is $2.91-$2.97
Quadvest acquisition closed October 1, 2026 for $542.7 million in cash; Cibolo Valley closing expected November 2, 2026
Quarterly dividend of $0.44 per share declared, payable December 1, 2026
Piedmont Realty Trust reported a third quarter 2026 net loss of $21.0 million, or $0.17 per diluted share, compared with $13.5 million, or $0.11 per share, a year earlier. The loss included a $20.2 million loss on early extinguishment of debt, while third quarter Core FFO rose to $0.39 per diluted share from $0.35, and the company raised its 2026 Core FFO outlook to $1.55-$1.57 per diluted share from $1.47-$1.53.
Net loss of $21.0 million ($0.17 per diluted share) for Q3 2026, vs. a $13.5 million loss ($0.11) in Q3 2025
Total revenues of $151.2 million for Q3 2026, vs. $139.2 million in Q3 2025
Core FFO of $0.39 per diluted share for Q3 2026, vs. $0.35 a year earlier; 2026 Core FFO outlook raised to $1.55-$1.57 from $1.47-$1.53
Cash rent roll up of 26.2% on Q3 2026 leasing; in-service portfolio 87.7% leased as of September 30, 2026, down from 88.9% on June 30, 2026
Azio AI Holdings told the SEC it believes it has regained compliance with Nasdaq's $2,500,000 minimum stockholders' equity requirement. The company cites a third-quarter 2026 business combination with Azio AI Corporation, warrant exercises, and stock issued under an equity purchase agreement, and it notes Nasdaq will keep monitoring compliance and may delist the stock if compliance is not shown at the next periodic report.
Nasdaq notified the company on April 29, 2026 that stockholders' equity was below the $2,500,000 minimum, based on its Form 10-K for 2025.
Nasdaq extended the deadline; the company had to file a public report demonstrating compliance on or before October 26, 2026.
In the third quarter of 2026 the company issued 2,460,351 common shares and 973,450 Series A Preferred shares in the Azio AI Corporation business combination, plus warrant exercises for 450,000 common shares and about 920,000 common shares
The company says actual results for the quarter ended September 30, 2026 may differ materially from preliminary unaudited figures.
JetBlue reported third-quarter 2026 operating revenue of $2.8 billion, up 21.1% from a year earlier, driven by higher yields. Its net loss widened to $257 million, or $0.68 per share, from $143 million, or $0.39 per share, as fuel costs rose 57.4% per gallon. The company also gave fourth-quarter and full-year 2026 outlook figures and said it expects further operating margin expansion in the fourth quarter.
Q3 2026 operating revenue was $2.8 billion, up 21.1% year-over-year; operating loss was $144 million versus $100 million a year earlier.
Net loss was $257 million ($0.68 per share) compared with $143 million ($0.39 per share) in Q3 2025.
Average fuel cost was $3.91 per gallon, 57.4% higher than a year earlier; Q4 2026 fuel price is estimated at $4.64 per gallon.
JetBlue expects 1 to 2 points of year-over-year operating margin expansion in the fourth quarter and reported $2.2 billion of liquidity at September 30, 2026.
Custom Truck One Source reported third-quarter 2026 revenue of $495.2 million, up 2.7% from a year earlier, and net income of $2.3 million compared with a net loss of $5.8 million in the same quarter of 2025. The company raised its 2026 Adjusted EBITDA and SER segment revenue guidance, but cut its 2026 levered free cash flow outlook to slightly positive from prior guidance of more than $50 million, as it increases rental fleet investment.
Q3 2026 revenue of $495.2 million, up from $482.1 million in Q3 2025; net income of $2.3 million versus a net loss of $5.8 million a year earlier
Q3 2026 Adjusted EBITDA of $110.9 million, up 15.6% year over year
2026 Adjusted EBITDA guidance raised to $447.5 million to $460 million from $437.5 million to $455 million
2026 levered free cash flow now expected to be slightly positive, versus prior guidance of more than $50 million; net rental fleet investment raised to $210 million to $230 million
TPG RE Finance Trust reported third quarter 2026 GAAP net income attributable to common stockholders of $5.8 million, or $0.08 per diluted share, and distributable earnings of $5.1 million, or $0.07 per share. Book value per common share fell to $10.85 from $10.95 at June 30, 2026, while dividends declared were $18.5 million, or $0.24 per share. The Board also approved a new $50.0 million share repurchase program on October 26, 2026.
GAAP net income attributable to common stockholders was $5.8 million, or $0.08 per diluted share, on 76.5 million diluted weighted average shares.
Distributable earnings were $5.1 million, or $0.07 per share, and $18.1 million, or $0.24 per share, before realized losses from loan resolutions.
Book value per common share was $10.85 at September 30, 2026, compared with $10.95 at June 30, 2026.
The Company originated eight loans and acquired one, with total loan commitments of $772.7 million, and repurchased 1,163,018 shares at a weighted average price of $8.00.
RadNet agreed on October 26, 2026 to acquire ONRAD, Inc., a teleradiology and in-hospital radiology staffing provider, for $350 million in cash and 5 million RadNet shares, subject to customary adjustments, plus an earnout of up to $210 million tied to ONRAD's 2027 Adjusted EBITDA. RadNet says ONRAD would add $190 million to $200 million of revenue and $60 million to $65 million of Adjusted EBITDA in its first year after closing, but the deal adds cash outflow and share issuance, and closing is expected in early 2027.
Upfront consideration of $350 million in cash and 5,000,000 shares of RadNet common stock, subject to customary adjustments and escrow holdbacks
Earnout of up to $210 million if ONRAD meets a target Post-Closing Annual Adjusted EBITDA for the fiscal year ending December 31, 2027, payable in cash, shares or both
RadNet expects ONRAD to add $190 million to $200 million of revenue and $60 million to $65 million of Adjusted EBITDA in its first year after closing
Closing expected in early 2027; the Hart-Scott-Rodino waiting period has expired, and a conference call is set for 8:00 a.m. Eastern Time on October 27, 2026
Greenbrier reported fourth-quarter revenue of $591.0 million, up from $576.5 million in the prior quarter, but diluted EPS fell to $0.27 from $0.60 as lower gross margin and $4 million of facility rationalization costs weighed on results. For fiscal 2026, net earnings attributable to Greenbrier were $79 million, or $2.49 per diluted share, down from $204.1 million in fiscal 2025, and the company guided fiscal 2027 EPS to $2.75 to $3.75 on revenue of $2.8 billion to $3.2 billion.
Q4 net earnings attributable to Greenbrier were $9 million, or $0.27 per diluted share; core diluted EPS was $0.39 excluding $0.12 per share of facility rationalization costs.
Railcar backlog was 14,000 units valued at an estimated $2.1 billion as of August 31, 2026, after 3,400 new orders in Q4.
Fiscal 2027 guidance: total revenue $2.8 billion to $3.2 billion, EPS $2.75 to $3.75, operating margin 7.0% to 7.5%.
Board approved a quarterly dividend of $0.34 per share, payable December 2, 2026, to holders of record as of November 11, 2026.
Northwest Bancshares reported third quarter 2026 net income of $51 million, or $0.34 per diluted share, up from $3 million a year earlier but down from $54 million in the second quarter. The company cited record total revenue and net interest income, while expenses and provisions rose from the prior quarter. The board also declared a $0.20 quarterly dividend.
Net income $51 million ($0.34 diluted EPS) vs. $3 million ($0.02) in Q3 2025 and $54 million ($0.36) in Q2 2026
Noninterest expense rose $5 million from Q2 2026, driven by FDIC premiums; annualized return on equity was 10.42% vs. 11.20% in Q2
Quarterly cash dividend of $0.20 per share payable November 17, 2026, to holders of record November 5, 2026
On October 25, 2026, Maplebear Inc.'s board decided to wind down Caper Cart operations to re-align resources toward the company's strategic priorities. The company expects pre-tax charges of $55 million to $80 million, mostly in the fourth quarter of 2026, with $30 million to $50 million expected to require future cash spending, and the company says actual amounts may differ materially from these estimates.
Pre-tax charges estimated at $55 million to $80 million, primarily in Q4 2026
Charges include $21 million to $36 million for contract terminations, $22 million to $27 million for asset impairments, and $12 million to $17 million for employee termination costs
$30 million to $50 million of the charges expected to result in future cash expenditures
Wind-down expected to be substantially completed by the end of Q2 2027; savings to be reinvested in strategic growth initiatives
Alexandria Real Estate Equities reported a third-quarter 2026 net loss of $638.5 million, or $3.74 per diluted share, compared with a loss of $234.9 million, or $1.38 per share, a year earlier. The loss includes $637.9 million of real estate impairment charges on assets held for sale, and FFO per diluted share, as adjusted, fell to $1.54 from $2.22, so shareholders face a large charge alongside lower core earnings, partly offset by strong leasing.
3Q26 net loss attributable to common stockholders was $638.5 million ($3.74 per diluted share), including $637.9 million of real estate impairment charges
3Q26 FFO per diluted share, as adjusted, was $1.54, versus $2.22 in 3Q25; year-to-date FFO per share was $5.00 versus $6.85
3Q26 total leasing volume was 1,236,030 RSF, the highest quarterly volume since 4Q24
Company expects 4Q26 annualized leverage of 5.6x to 6.2x and reported liquidity of $4.56 billion as of September 30, 2026
Cincinnati Financial reported third-quarter 2026 net income of $459 million, or $2.96 per share, down from $1.122 billion, or $7.11 per share, a year earlier. Non-GAAP operating income was $443 million, or $2.86 per share, versus $449 million, or $2.85 per share, while the property casualty combined ratio rose to 90.9% from 88.2%.
Q3 2026 net income $459 million ($2.96 per share) vs. $1.122 billion ($7.11 per share) in Q3 2025, mainly due to lower investment gains.
Q3 2026 non-GAAP operating income $443 million ($2.86 per share) vs. $449 million ($2.85 per share) in Q3 2025.
Q3 2026 property casualty combined ratio 90.9% vs. 88.2%, including 7.0 points of higher catastrophe losses.
Nine-month non-GAAP operating income rose 38% to $997 million; book value per share was $105.42 at September 30, 2026.
The Hartford reported third quarter 2026 net income available to common stockholders of $1.3 billion ($4.82 per diluted share), up 23% from a year earlier, including a $497 million pre-tax gain from commuting its asbestos and environmental adverse development cover. Core earnings, which exclude that gain, fell 6% to $956 million ($3.50 per diluted share), and the company raised its quarterly common dividend 12% to $0.67.
Net income available to common stockholders was $1.3 billion ($4.82 per diluted share), up from $1.1 billion ($3.77) in third quarter 2025.
Core earnings were $956 million ($3.50 per diluted share), down from $1,022 million ($3.59 per diluted share).
Quarterly common dividend increased 12% to $0.67 per share, payable Jan. 5, 2027, to holders of record on Dec. 1, 2026.
Business Insurance combined ratio was 91.3 versus 88.8 a year earlier; Personal Insurance combined ratio was 93.2 versus 88.7. Mo Tooker will succeed Christopher Swift as CEO on March 1.
Clearwater Paper reported third-quarter 2026 net sales of $385 million, down from $399 million a year earlier, and a net loss of $2 million, or $0.10 per diluted share, compared with a $53 million loss in the prior-year quarter that included a goodwill impairment. The company guided fourth-quarter Adjusted EBITDA from continuing operations to $10 million to $20 million, and Chief Financial Officer Sherri Baker intends to resign effective November 13, 2026.
Q3 2026 net sales were $385 million versus $399 million in Q3 2025; net loss was $2 million ($0.10 per diluted share) versus $53 million ($3.30 per share) a year earlier.
Adjusted EBITDA from continuing operations was $24 million versus $18 million in Q3 2025.
Q4 2026 Adjusted EBITDA is projected at $10 million to $20 million, citing lower seasonal shipments and Augusta mill disruptions that continued into October.
CFO Sherri Baker informed the company on October 22, 2026, that she intends to resign, effective at the close of business on November 13, 2026.
Brixmor reported third-quarter 2026 results with total revenues of $359.6 million, up from $340.8 million a year earlier, and Nareit FFO of $184.6 million, or $0.60 per diluted share, up from $0.56. Net income attributable to the company fell to $0.28 per diluted share from $0.31, and the company raised its 2026 Nareit FFO per share expectations to $2.36 to $2.38 from $2.35 to $2.37.
Diluted net income per share was $0.28 for the quarter versus $0.31 a year earlier; nine-month diluted EPS was $0.94 versus $0.81.
Same property NOI rose 6.6% for the quarter, and leased occupancy reached a record 95.6%.
2026 same property NOI growth expectation raised to 5.50% to 5.75% from 5.00% to 5.75%.
Quarterly dividend increased 7.3% to $0.3300 per share, payable January 15, 2027.
Sun Communities reported third-quarter 2026 results, with Core FFO per share of $2.35 and net income of $1.00 per diluted share including a loss from discontinued operations. The company completed the sale of its UK business on September 22, 2026, which is reflected in a nine-month net loss attributable to common shareholders of $880.7 million, or $7.14 per diluted share. Shareholders should weigh the quarter's year-over-year gains against that large nine-month loss.
Q3 2026 net income per diluted share was $1.00, or $1.07 from continuing operations, compared with $0.07 and a $0.45 loss from continuing operations a year earlier.
Q3 2026 Core FFO per share was $2.35, up from $2.28 in Q3 2025; same property NOI grew 3.6% for the quarter.
Nine-month net loss attributable to common shareholders was $880.7 million, or $7.14 per diluted share, versus net income of $1.2 billion a year earlier.
Updated 2026 Core FFO per share guidance is $6.97 to $7.05; North America same property NOI growth guidance is 4.9% to 5.3%.
Capital Bancorp reported unaudited third-quarter 2026 results, with GAAP net income of $13.1 million, down 12.9% from $15.1 million a year earlier, and diluted EPS of $0.80, down from $0.89. Non-GAAP core EPS was $0.89, up 2.3% from the prior quarter, after excluding $1.6 million of merger-related expenses tied to the pending all-stock merger with Peoples Bancorp. The company also declared a $0.14 per share dividend.
GAAP net income of $13.1 million and diluted EPS of $0.80 in Q3 2026, versus $15.1 million and $0.89 in Q3 2025
Core diluted EPS of $0.89 in Q3 2026, up from $0.87 in Q2 2026 and $0.72 in Q3 2025
Net interest income of $53.1 million, up 4.2% from Q2 2026; net interest margin of 5.81%
Dividend of $0.14 per share payable November 25, 2026 to holders of record on November 9, 2026
Principal Financial Group reported third quarter 2026 results, with GAAP net income attributable to PFG of $631.9 million, or $2.91 per diluted share, up from $213.8 million a year earlier. Non-GAAP operating earnings per diluted share rose 6% to $2.22, but non-GAAP net income excluding exited business fell 24% to $354.8 million, and results include a $276.7 million pre-tax loss from the disposition of its Chilean annuities business. The company also raised its fourth quarter common stock dividend to $0.85 per share.
GAAP net income attributable to PFG was $631.9 million, or $2.91 per diluted share, versus $213.8 million, or $0.95, in third quarter 2025; the company cites a $276.7 million pre-tax loss on the Chilean annuities disposition.
Non-GAAP operating earnings per diluted share were $2.22, up 6% from $2.10; excluding significant variances, it was $2.49, up 7% from $2.32.
Non-GAAP net income attributable to PFG, excluding exited business, was $354.8 million, down 24% from $465.6 million.
Fourth quarter 2026 common stock dividend of $0.85 per share, a one-cent increase, payable December 18, 2026 to holders of record as of December 2, 2026.
Faraday Future (FFAI) completed the sale of its robotics business to FF EAI Robotics Ecosystem Inc. (FFR) on October 23, 2026. FFR, which FFAI controls, paid a purchase price of $200 million, settled in FFR common and non-voting preferred stock, and the transaction was a related-party deal. Shareholders should note the dilution from the share issuance and that FFAI no longer owns the robotics business, which now trades under FFR on Nasdaq.
Closing date was October 23, 2026; purchase price was $200 million, adjusted for outstanding FF Robotics options.
FFR issued 1,315,313 common shares and 65,475 non-voting preferred shares to the FFAI subsidiary, equal to 66,790,313 shares on an as-converted basis at $2.246 per share.
Yueting Jia and Jiawei Wang entered employment agreements with FF Robotics; FFR's new board structure gives FF Global Partners LLC the right to designate four of seven directors.
FFR gave first-time 2026 guidance of approximately 2,000 robots in sales and shipments.
FF EAI Robotics Ecosystem (FFR) closed its acquisition of RobotCo, the robotics business of Faraday Future, on October 23, 2026, issuing 1,315,313 common shares and 65,475 Series C Preferred shares with no cash paid. The Series C Preferred is convertible into 65,474,624 common shares, subject to limits in Item 5.03, so the deal carries significant potential share issuance for current holders, while the company also gave its first full-year 2026 guidance of approximately 2,000 robots.
Acquisition closed October 23, 2026; FFR issued 1,315,313 common shares and 65,475 Series C Preferred shares to the Cayman Seller, with no cash proceeds.
Series C Preferred is convertible into 65,474,624 common shares, subject to adjustment and the limits described in Item 5.03.
Yueting Jia appointed Chief Executive Officer with a $500,000 base salary and $500,000 target bonus; Jiawei (Jerry) Wang became Executive Chairman.
Press release says 2026 robot sales and shipments are expected to be approximately 2,000 units, and October 2026 shipments are expected to exceed 300 units.
Peraso Inc. agreed on October 26, 2026 to sell shares, pre-funded warrants and common warrants to Nant Capital, LLC for expected gross proceeds of about $10 million, before offering expenses. The deal, expected to close on or about October 28, 2026, adds cash but also issues a large number of new shares and warrants, which would dilute existing shareholders. It also gives Nant the right to designate board members while its stake stays at or above 5% of outstanding common stock.
Units priced at $0.5034, including Shares, Pre-Funded Warrants and Common Warrants; 3,271,355 shares and pre-funded warrants for 16,593,563 shares, plus common warrants for up to 19,864,918 shares
Common warrants have an exercise price of $0.3784 per share and a two-year term from issuance
Nant may designate two board members while it owns at least 16.7% of common stock, and one while it owns at least 5% but less than 16.7%; no designee has been appointed yet
Closing expected on or about October 28, 2026, subject to closing conditions; proceeds are for working capital and general corporate purposes
SHF Holdings, doing business as Safe Harbor, signed a non-binding term sheet on October 26, 2026 under which Opifex Media Inc. would become a wholly owned subsidiary in a transaction expected to be accounted for as a reverse acquisition. Opifex security holders would own 85% of the combined company and existing Safe Harbor holders 15%, on a fully diluted basis before capital raised at closing, and the term sheet does not obligate either party to complete the deal. The filing also disclosed that Series B preferred conversions issued shares exceeding 5% of common stock outstanding, adding to dilution for existing shareholders.
Non-binding term sheet signed October 26, 2026; Opifex would merge into a newly formed subsidiary of Safe Harbor and holders would receive Safe Harbor common stock.
Opifex holders would own 85% and existing Safe Harbor holders 15% at closing, with the Safe Harbor share adjustable within 12.5% to 17.5%.
From July 1 to October 23, 2026, 23,914,988 common shares were issued on conversion of 6,545 Series B preferred shares for no additional consideration; 24,942,735 shares were outstanding as of October 23, 2026.
Nasdaq granted an additional compliance period through April 19, 2027 to regain the $1.00 minimum bid price requirement; the term sheet contemplates a 45-day exclusivity period.
On October 26, 2026, GameSquare completed its acquisition of FanEngine's IP assets in exchange for 5,439,416 newly issued common shares, which the company says equals 30% of its shares outstanding after closing. Sellers may also earn up to 1,410,218 more shares and up to $50 million in cash based on revenue and net income milestones, so existing shareholders face significant dilution. The company reiterated its 2027 guidance of revenue over $150 million and adjusted EBITDA of more than $30 million.
Closing completed October 26, 2026; 5,439,416 shares issued to Seller Securityholders, 30% of shares outstanding after closing.
Earnout: up to 1,410,218 additional shares and up to $50 million in cash, tied to revenue and net income milestones through 2028.
Stockholders approved the share issuance on October 22, 2026, with 4,680,673 votes for and 896,967 against.
Marco Baccanello and Benjamin Hugo joined the board; the company reiterated 2027 guidance of revenue over $150 million and adjusted EBITDA above $30 million.
MainStreet Bancshares reported third quarter 2026 net income of $3.6 million, or $0.43 per common share, down from $4.5 million, or $0.52, a year earlier. Net interest income rose to $18.8 million, but the company added a $1.9 million provision for credit losses, which it attributed to targeted credit remediation in commercial real estate.
Q3 2026 EPS of $0.43 versus $0.52 in Q3 2025; nine-month EPS of $1.48 versus $1.29
Net interest income of $18.8 million, up from $17.1 million a year earlier and the fourth consecutive quarterly increase
$1.9 million provision for credit losses reduced EPS by $0.21
Non-performing loans were $92.0 million at September 30, 2026, versus $23.4 million at September 30, 2025
Xencor said its current operating plans give it cash to fund research, development and operations into 2029. The company also released updated Phase 1 results for XmAb819 in advanced clear cell renal cell carcinoma, reporting confirmed objective response rates of 30.0% to 45.5% across three dose levels. The data are early and come from small groups, and the filing reports high rates of grade 3 or higher adverse events.
Cash expected to fund R&D and operations into 2029, based on current operating plans.
Confirmed objective response rate: 30.0% at 100 μg/kg (n=30), 44.0% at 200 μg/kg (n=25), 45.5% at 400 μg/kg (n=11).
Grade 3 or higher treatment-emergent adverse events occurred in 82.4% of expansion-dose patients (n=68); one treatment discontinuation due to cytokine release syndrome was reported.
Full 400 μg/kg analysis expected during 1H 2027 (20+ patients); a potential registration-enabling study is planned to start in 2027.
Acumen Pharmaceuticals reported a third-quarter 2026 net loss of $25.4 million, narrower than $26.5 million a year earlier, and cash, cash equivalents and marketable securities of $78.6 million at September 30, 2026, down from $110.2 million at June 30, 2026. The company expects the cash to fund current clinical and operational activities into early 2027 and said topline results from its Phase 2 ALTITUDE-AD study are expected in November 2026.
Net loss was $25.4 million for the quarter ended September 30, 2026, versus $26.5 million a year earlier; loss per share was $0.35 versus $0.44.
Cash, cash equivalents and marketable securities were $78.6 million at September 30, 2026, versus $110.2 million at June 30, 2026, with runway expected into early 2027.
R&D expenses were $21.1 million versus $22.0 million a year earlier, mainly due to lower manufacturing, materials and CRO costs tied to ALTITUDE-AD.
Topline ALTITUDE-AD Phase 2 results for sabirnetug are expected in November 2026.
EQT agreed to acquire Range Resources in an all-stock merger, with each Range share exchanged for 0.987 EQT shares and EQT holders owning about 73% of the combined company. The deal is subject to shareholder votes at both companies, regulatory approvals, and other closing conditions, with closing expected in the first quarter of 2027, so the transaction would reshape EQT's ownership and scale if completed.
Each Range common share converts into 0.987 EQT common shares; EQT holders expected to own about 73% and Range holders about 27%
Termination fees: Range would pay EQT $423 million and EQT would pay Range $1,148 million in certain circumstances
Expected to close in the first quarter of 2027; either party may terminate if not completed by October 25, 2027, extendable to April 25, 2028
Expected annual synergies of $325 million within two years; Range CEO Dennis Degner and one other Range designee to join EQT's board
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.